RxDoctor Payments Data

Nathaniel Fleischner, MD

Internal Medicine · Royal Palm Beach, FLNPI 1083880926

Payments from drug & device makers

$583in general payments, 2019–2025

Across 31 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$160
  • Lilly USA, LLC$85
  • GSK$82
  • Exact Sciences$78
  • Abbott$46
  • Boehringer Ingelheim$40
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$583 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$27,213
Medicare patients
76
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$86,296
JardianceEmpagliflozin66$82,377
OzempicSemaglutide47$58,554
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$56,178
RybelsusSemaglutide18$27,379
XareltoRivaroxaban35$23,073
JanuviaSitagliptin Phosphate15$20,376
VraylarCariprazine Hcl14$19,449
LinzessLinaclotide18$17,634
TradjentaLinagliptin13$15,647
EntrestoSacubitril/Valsartan14$10,821
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,082
LantusInsulin Glargine,hum.Rec.Anlog18$5,005
Novolog FlexpenInsulin Aspart14$3,967
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$40$98,02479 claims
PfizerEliquis$39$86,29696 claims
Novo NordiskOzempic, Rybelsus$160$85,93365 claims
GSKTrelegy Ellipta$82$56,17859 claims
AbbVieVraylar, Linzess, Synthroid$17$38,67356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Royal Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →